Moxibac Tablet 400 mg

Moxibac (Moxifloxacin Hydrochloride 400 mg) is a potent antibacterial tablet manufactured by Popular Pharmaceuticals Ltd. Priced at ৳70.00 per unit, this broad-spectrum antibiotic treats respiratory, skin, and intra-abdominal infections. Its 10-tablet strip costs ৳700.00, making it accessible for diverse bacterial conditions.

As a 4th-generation fluoroquinolone, Moxibac inhibits bacterial DNA gyrase, effectively combating Gram-positive, Gram-negative, and atypical pathogens. Learn more about Moxifloxacin Hydrochloride mechanisms. It’s prescribed for sinusitis, pneumonia, and pelvic inflammatory disease with 7-21 day courses depending on severity.

Dosage guidelines:

• Acute bacterial sinusitis: 400 mg once daily for 7-10 days
• Skin infections: 7-21 days treatment
• Pelvic inflammatory disease: 14-day regimen

Avoid antacids and iron supplements within 4 hours of dosing. Concurrent NSAIDs may increase seizure risk. Common side effects include nausea (10-15% users) and headaches. Store tablets below 30°C in blister packaging to maintain efficacy.

Pregnant women should avoid Moxibac due to FDA Category C risks. For alternative tablet formulations, consult healthcare providers. Emergency overdose management requires immediate medical attention despite limited toxicity data.

Adults: 400 mg tablet once daily. Duration: 7-10 days for sinusitis, up to 21 days for skin infections. No dose adjustment needed in renal/hepatic impairment. Administer 2 hours before/after iron/zinc supplements or antacids.

Common side effects of Moxibac include nausea, vomiting, diarrhea, headache and dizziness.

US FDA pregnancy category C. Potential fetal risk in animal studies. Avoid during pregnancy/lactation due to secretion in breast milk.

Avoid sunlight exposure (photosensitivity risk). Monitor blood glucose in diabetics. May exacerbate myasthenia gravis. Discontinue if neuropsychiatric symptoms occur.

Assess renal function in elderly. Contraindicated under 18 years due to arthropathy risk. No dose adjustment in hepatic/renal impairment.